In March 2014 the FDA approved apremilast (Otezla) for use in psoriatic arthritis based on three large"Palace" trials involving 1493 psoriatic arthritis patients. This ACR Hotline reviews the drugs use, efficacy, and toxicity.
Hemophagocytic lymphohistiocytosis(HLH) is a rare complication of many disorders. In children, systemic JIA is by far the most common cause of HLH.
The generic drug manufactuer Actavis joins Teva and Mylan with their lauch of celecoxib (Celebrex)in 50 mg, 100 mg, 200 mg and 400 mg capsules. In 2013 celecoxib was the 21st leading prescribed drug in the U.S. with $2.4 billion in sales as of mid 2014.
Gout's often told tale of a nocturnal rapid onset and dramatic pain provoked by a bed sheet, is studied in detail by Choi and the Boston online gout study. This report shows that more than half the attacks occur late night and are unrelated to alcohol or purine intake.
Older estimates suggested it would cost $1 billion to develop a new drug. ThisNY Times article discusses newer estimates claiming it cost 2.6 billion to bring a new drug to market.
Congress investigates why the price of more than 1,200 generic medications increased an average 448% betweeen 2013-2014.http://buff.ly/1v56VUt
WASHINGTON - Pregnant women are about to get easier-to-understand information on how safe their medicine is for baby.
Dr James Watson, of Watson and Crick double-stranded DNA fame, has offered up his Nobel prize for auction, with the intention of donating the proceeds to medical institutions which he says has nurtured him, and scores of others, during his career.
The patients out of pocket costs for "Specialty Drugs" will increase significantly in 2015.
In September 2014, the participating members of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Program funded a research Network to implement the program.
Ibuprofen has a corner on the over-the-counter pain market, accounting for one-third of OTC analgesics in the U.S.
Salk scientists identify how immune cells use two critical receptors to clear dead cells from the body, pointing the way to new autoimmune and cancer therapies.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
